Complete and Durable Response to Combined Chemo/Radiation Therapy in EGFR Wild-Type Lung Adenocarcinoma with Diffuse Brain Metastases

Diagnostics

Gianmaria Miolo¹  Mariangela De Zorzi²  Valli De Re²  Giuseppe Corona²  Laura Caggiari²  Antonio Cossu³  MariaFilomena Dedola⁴  DavideAdriano Santeufemia⁵  Giovanni Baldino⁵  Milena Casula⁶  Giuseppe Palmieri⁶  MariaCristina Sini⁶ 

[1] Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via F. Gallini 2, 33081 Aviano, Italy;Immunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Via F. Gallini 2, 33081 Aviano, Italy;Operative Unit of Pathology, Azienda Ospedaliero Universitaria Sassari, Via Matteotti 60, 07100 Sassari, Italy;Radiotherapy Unit, Azienda Ospedaliero Universitaria Sassari, Via Matteotti 60, 07100 Sassari, Italy;SSD Oncology, Alghero General Hospital, 07041 Alghero, Italy;Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Traversa La Crucca 3, 07100 Sassari, Italy;

关键词: lung cancer;    EGFR;    brain metastases;    radiotherapy;    chemotherapy;    CDH1;    TP53;    tumor mutational burden;   

DOI  :  10.3390/diagnostics9020042

来源: DOAJ

【 摘 要 】

Most non-small-cell lung cancer (NSCLC) patients are likely to develop brain metastases during the course of their illness. Currently, no consensus on NSCLC patients’ treatment with brain metastasis has been established. Although whole brain radiotherapy prolongs the median survival time of approximately 4 months, a cisplatin-pemetrexed combination may also represent a potential option in the treatment of asymptomatic NSCLC patients with brain metastases. Herein, we report the case of a non-smoker male patient with multiple, large and diffuse brain metastases from an “epidermal growth factor receptor (EGFR) wild-type„ lung adenocarcinoma who underwent an overly aggressive chemo/radiation therapy. This approach led to a complete and durable remission of the disease and to a long survival of up to 58 months from diagnosis of primary tumor. The uncommon course of this metastatic disease induced us to describe its oncological management and to investigate the molecular features of the tumor.

【 授权许可】

Unknown